Bayer Reports the Initiation of the P-III (QUANTI) Trials for Gadoquatrane as a Contrast Agent for Magnetic Resonance Imaging
Shots:
- The P-III (QUANTI) clinical trials evaluate the safety & efficacy of gadoquatrane (0.04mmol Gd/kg bw) vs GBCAs (0.1mmol Gd/kg) to be used in radio-imaging. The QUANTI study is composed of 2 P-III trials incl. (QUANTI CNS) & (QUANTI OBR) along with 1 pediatric study
- (QUANTI CNS) evaluates gadoquatrane in patients with known or highly suspected disorders of the CNS whereas (QUANTI OBR) analyses gadoquatrane in contrast-enhanced MRI for different body areas, incl. head & neck, thorax, abdomen, pelvis & extremities
- Gadoquatrane is a contrast agent which has a distinct tetrameric structure with high stability & relaxivity and has the ability to lower clinical gadolinium dose in contrast-enhanced MRI for patients
Ref: Busineswire | Image: Bayer
Related News:- Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
